Peptides as Next Growth Frontier for Hims & Hers as GLP-1 Business Evolves
TL;DR Summary
Hims & Hers Health is pursuing peptides as a potential growth driver as its high‑margin compounded GLP‑1 business matures. The FDA plans a July 2026 review of peptides for possible inclusion on the 503A bulk list, a step that could enable regulated, physician‑led peptide therapy and unlock new revenue, though progress is not immediate and clinical evidence is limited. The company bought a peptide facility in 2025 and intends to steer users toward branded therapies rather than proprietary compounded GLP‑1 drugs.
- RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves CNBC
- FDA to weigh easing limits on unproven peptides promoted by RFK Jr. NBC News
- Hims & Hers stock jumps as U.S. moves forward with plan to reassess popular peptides MarketWatch
- The Trump administration is looking to experts to weigh in on peptides Scientific American
- FDA advisory committee set to weigh taking action on certain unapproved peptides Fierce Pharma
Reading Insights
Total Reads
0
Unique Readers
17
Time Saved
3 min
vs 4 min read
Condensed
88%
668 → 81 words
Want the full story? Read the original article
Read on CNBC